VITAMIN A (200,000 IU) AND VITAMIN E (40 IU) ORAL LIQUID PREPARATION CAPSULE

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

VITAMIN A (RETINYL PALMITATE); VITAMIN E (DL-ALPHA TOCOPHERYL ACETATE)

Disponibbli minn:

NUTRICORP INTERNATIONAL

Kodiċi ATC:

A11JA

INN (Isem Internazzjonali):

COMBINATIONS OF VITAMINS

Dożaġġ:

200000UNIT; 40UNIT

Għamla farmaċewtika:

CAPSULE

Kompożizzjoni:

VITAMIN A (RETINYL PALMITATE) 200000UNIT; VITAMIN E (DL-ALPHA TOCOPHERYL ACETATE) 40UNIT

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

500

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

VITAMIN A

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0225696007; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2016-04-06

Karatteristiċi tal-prodott

_ _
_Page 1 of 37_
PRODUCT MONOGRAPH
PR
VITAMIN A (200,000 IU) AND VITAMIN E (40 IU) ORAL LIQUID PREPARATION
VITAMIN A AND VITAMIN E SOFTGEL CAPSULES
200,000 IU Vitamin A (all-trans-retinyl palmitate) and 40 IU Vitamin E
(all-rac-alpha-
tocopheryl acetate)
One IU of Vitamin A is equivalent to the activity of 0.3 mcg of
all-trans-retinol
ATC code: Vitamins – A11
Nutricorp International
4025 Rhodes Drive
Windsor, Ontario
N8W 5B5
Date of Preparation:
April 5, 2016
Submission Control No: 167924
_ _
_ _
_Page 2 of 37_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................4
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................5
DRUG INTERACTIONS
....................................................................................................6
DOSAGE AND ADMINISTRATION
................................................................................7
OVERDOSAGE
..................................................................................................................8
ACTION AND CLINICAL PHARMACOLOGY
..............................................................9
STORAGE AND STABILITY
..........................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................12
PART II: SCIENTIFIC INFORMATION
...............................................................................14
PHARMACEUTICAL INFORMATION
.......................................................